<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Dose-escalation schedule and dose-limiting toxicities</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Dose (mg/kg)</th>
    <th>Prophylaxis</th>
    <th>Evaluable patients (
     <italic>n</italic> = 48*)
    </th>
    <th>Patients with DLT</th>
    <th>Dose-limiting toxicity</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>0.1</td>
    <td>None</td>
    <td>3</td>
    <td>0</td>
    <td>–</td>
   </tr>
   <tr>
    <td>0.2</td>
    <td>None</td>
    <td>8</td>
    <td>0</td>
    <td>–</td>
   </tr>
   <tr>
    <td>0.4</td>
    <td>None</td>
    <td>5</td>
    <td>2</td>
    <td>Grade 3 febrile neutropenia</td>
   </tr>
   <tr>
    <td>0.8</td>
    <td>None</td>
    <td>2</td>
    <td>2</td>
    <td>Grade 4 neutropenia;
     <break/>Grade 2 peripheral sensory neuropathy
    </td>
   </tr>
   <tr>
    <td>0.4</td>
    <td>Steroids</td>
    <td>3</td>
    <td>0</td>
    <td>–</td>
   </tr>
   <tr>
    <td>0.7</td>
    <td>Steroids</td>
    <td>3</td>
    <td>0</td>
    <td>–</td>
   </tr>
   <tr>
    <td>1.0</td>
    <td>Steroids</td>
    <td>3</td>
    <td>1</td>
    <td>Grade 3 febrile neutropenia</td>
   </tr>
   <tr>
    <td>1.0</td>
    <td>Steroids + G-CSF</td>
    <td>3</td>
    <td>0</td>
    <td/>
   </tr>
   <tr>
    <td>1.4</td>
    <td>Steroids + G-CSF</td>
    <td>6</td>
    <td>1</td>
    <td>Grade 4 thrombocytopenia</td>
   </tr>
   <tr>
    <td>1.8</td>
    <td>Steroids + G-CSF</td>
    <td>12</td>
    <td>2</td>
    <td>Grade 3 febrile neutropenia;
     <break/>Grade 3 febrile neutropenia plus grade 4 neutropenia and thrombocytopenia
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>*One patient (0.2 mg/kg cohort) discontinued from study prior to the safety evaluation performed 21 days following the first administration of IMGN529 and was thus non-evaluable for DLT assessment</p>
 </table-wrap-foot>
</table-wrap>
